What is this summary about? This is a plain language summary of an article originally published in the Journal of Urology. Overactive bladder (also called OAB) has been treated with the same type of medicine for more than 40 years. Vibegron is in a newer class of medicine for treating overactive bladder called beta-3 adrenergic receptor agonists. The EMPOWUR study was a phase 3 clinical trial that looked at whether vibegron was safe and improved symptoms in people with overactive bladder. Vibegron was approved by the US Food and Drug Administration (also called the FDA) based in part on the results of this study. What were the results? Participants of the EMPOWUR study who took vibegron showed an improvement in their overactive bladder symptoms. These symptoms include the number of urinations (peeing), the urgent need to urinate, and accidental urination (bladder leaks). After 12 weeks, participants who took vibegron had significantly greater improvements than participants who took placebo. What do the results mean? This study suggests that vibegron could safely improve symptoms in people with overactive bladder. Clinical Trial Registration: NCT03492281 (ClinicalTrials.gov).
Journal of comparative effectiveness research. 2023 Aug 10 [Epub ahead of print]
David Staskin, Jeffrey Frankel, Steven G Gregg, Susann Varano, Janet Owens-Grillo
Tufts University School of Medicine, Boston, MA, USA., Seattle Urology Research Center, Seattle, WA, USA., National Association for Continence, Charleston, SC, USA., Clinical Research Consulting, Milford, CT, USA., Sumitomo Pharma America, Inc. (formerly Urovant Sciences, Inc.), Marlborough, MA, USA.